Please refer attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Emmessar Biotech & Nutrition Ltd approved the unaudited financial results for the quarter and half year ended September 30, 2025 at their meeting held on November 12, 2025. Total Income for Q2 FY26 stood at around Rs. 84.99 lakhs, compared to about Rs. 125.74 lakhs in the corresponding quarter of the previous year, indicating a notable sequential and year-on-year decline. Segment-wise reporting shows the company operates through different business segments, though exact breakdowns are hard to read. The Statutory Auditors, M/s. V. Nagarajan & Co., issued a clean Limited Review Report with no qualifications or adverse remarks. A Cash Flow Statement for the half year was also filed. Total Assets stood at Rs. 951.58 lakhs as on the reporting date.
The year-on-year fall in quarterly revenue is a concern for shareholders, though the clean audit review provides some comfort. Investors should watch whether the company can reverse the decline in the coming quarters.